Pd1/pd-l1 axis in uro-oncology

Junker K, Eckstein M, Fiorentino M, Montironi R (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Current Drug Targets Bentham Science Publishers

Book Volume: 21

Pages Range: 1293-1300

Journal Issue: 13

DOI: 10.2174/1389450121666200326123700

Abstract

The immune system is important to control tumor development and progression in humans. However, tumor cells and cells of the tumor microenvironment can induce immune escape mecha-nisms including activation of immune checkpoints such as PD-1/PD-L1. Based on this knowledge, new immune therapies, including PD-1 and PD-L1 inhibition, have been developed and are already recommended as a standard treatment in metastatic bladder and kidney cancer patients. In addition to its role as a therapeutic target, PD-L1 seems to be a prognostic parameter although data are controversial. Only little is known about signaling pathways inducing PD-L1 expression in tumor cells on one hand and about its functional role for tumor cells itself. However, the understanding of the complex biological function of PD-L1 will improve therapeutic options in urological malignancies. This review is giving an overview of the current knowledge concerning the PD-1/PD-L1 axis in urological tumors including bladder, kidney, prostate, testicular and penile cancer.

Authors with CRIS profile

Markus Eckstein Institute of Pathology

Involved external institutions

Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) University of Bologna / Università di Bologna IT Italy (IT) Università Politecnica delle Marche (UNIVPM) / Marche Polytechnic University IT Italy (IT)

How to cite

APA:

Junker, K., Eckstein, M., Fiorentino, M., & Montironi, R. (2020). Pd1/pd-l1 axis in uro-oncology. Current Drug Targets, 21(13), 1293-1300. https://doi.org/10.2174/1389450121666200326123700

MLA:

Junker, Kerstin, et al. "Pd1/pd-l1 axis in uro-oncology." Current Drug Targets 21.13 (2020): 1293-1300.

BibTeX: Download